| 标题 |
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:Lancet Infect Dis 作者:Aboud M, Kaplan R, Lombaard J, Zhang F, Hidalgo JA, Mamedova E, Losso MH, Chetchotisakd P, Brites C, Sievers J, Brown D, Hopking J, Underwood M, Nascimento MC, Punekar Y, Gartland M, Smith K 出版日期:2019-02-04 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)